The Vigor is Back
Minimally Invasive TAVR Procedure Helps Get Florham Park Woman Back on Her Feet
When Ida Williams saw her family doctor for a head cold, she wasn’t expecting any unusual news. But when Ida’s physician listened to her lungs and heart during what would have been an otherwise normal office visit, he heard a heart murmur – often a sign of heart valve disease – and recommended the 77-year-old retiree seek further treatment.
While the Florham Park resident had been told three years prior she had a slight heart murmur, after hearing the news a second time, Ida decided it was time for more information.
“I wanted to know just how bad it was,” says Ida.
After consulting with a cardiologist and undergoing testing, Ida was referred to cardiac surgeon Mark J. Russo, MD,, a nationally renowned heart surgeon who performs traditional open heart surgery and minimally invasive catheter-based procedures.
During Ida’s appointment with Dr. Russo, she was diagnosed with aortic stenosis. After completing a comprehensive assessment and additional testing, Dr. Russo explained to Ida the various options for treatment and recommended she undergo Transcatheter Aortic Valve Replacement (TAVR).
A minimally invasive, FDA-approved procedure, TAVR is used to treat severe aortic stenosis. During the procedure, a synthetic or artificial valve is collapsed and threaded through a blood vessel, usually through the groin, to the heart on the tip of a catheter. Physicians use state-of-the-art imaging technology to visualize its precise placement and expand the new valve. It begins to function immediately and works like a normal healthy valve that allows for proper blood flow through the chambers of the heart. Because no chest incision is required, recovery is minimal. Patients experience less pain and are often able to return home the following day.
Having performed more than 500 successful TAVR procedures, Dr. Russo and his team from Barnabas Health are among the most experienced in the U.S. In an effort to offer greater access to this life-saving therapy, Dr. Russo along with Dr. Bruce Haik, Director of Cardiac Catheterization Labs for Barnabas Health and Dr. Chunguang Chen, Director of Cardiac Imaging for Barnabas Health, now perform TAVR at Saint Barnabas Medical Center. Ida was the first patient to undergo the TAVR atthe facility.
Today, she credits Dr. Russo and the nurses and staff with calming her nerves and getting her back on her feet.
“Everybody was wonderful. I was scared, but the nurses reassured me I was going to be alright. They were all angels,” she says. “I wouldn’t dream of going to another hospital.”
And although, Ida didn’t realize the impact her heart condition was having on her life, she couldn’t be more pleased with the outcome.
“I used to get out of breath a lot. If I was up moving around, I’d need to sit down for a few minutes here and there because I’d be huffing and puffing,” she says. “I never knew it was related to my heart, but since the surgery, I’m doing it all with ease. I feel much, much better – like I could run up a bunch of steps. It’s a brand new me!”
Please call us at (732) 235-7231 or send an email here.
For your convenience, Telemedicine Consults are available for patients. To schedule a consultation, please call 732-235-7231.
Minimally invasive valve surgery is a specialized approach to treating heart valve disease that avoids the need to “crack the chest.” This method uses sophisticated instruments to perform the surgery through a smaller incision at the side of the chest and offers the patients less pain and faster recovery. We perform nearly all of our isolated valve surgeries minimally invasively.
An aortic aneurysm is a bulging, weakened area in the wall of main blood vessel in the body. The risk of aortic catastrophe, including dissection and rupture, increases dramatically with an aneurysm. Surgery may be recommended when the aorta is larger than 4.5-6 cms. Factors including family history, lifestyle, and need for other heart surgery guide decisions about surgery.
Transcatheter aortic valve replacement (TAVR), also known as transcatheter aortic valve implantation (TAVI), is a minimally invasive approach to the treatment of aortic stenosis. In most patients, it requires no incision and typically patients are discharged within 1 day. Dr Russo is among the most experienced TAVR surgeons in the US.
A “bypass” or “cabg” surgery is the most commonly performed heart surgery. It is necessary when the coronary arteries, which provide blood to the heart become narrow preventing sufficient blood from passing through, and thus depriving the heart of oxygen and nutrients. RWJUH has CABG outcomes that exceed national benchmarks.
When other treatments are insufficient, a heart transplant is a surgical procedure offered to patients with the most severe damage to the heart. RWJUH is one of a limited number of centers in the US that offer advance heart failure surgery, including heart transplant. Dr. Russo has participated in 500+ successful transplant surgeries.
The MitraClip device is a small clip that helps your mitral valve to close more completely. The procedure does not require opening the chest or stopping the heart. Instead, through a vein in the leg, a thin tube (called a catheter) is guided to the mitral valve. Dr. Russo is among the highest volume Mitraclip operators in the Northeast.
Transcatheter aortic valve replacement vs OMM (randomized) for asymptomatic severe AS The EARLY TAVR trial (Edwards) looks at transcatheter aortic valve replacement (TAVR) as an effective treatment for patients with asymptomatic aortic stenosis. Patients are randomized to either treatment with TAVR or clinical surveillance until the develop symptoms, at which point they are eligible to be treated with TAVR. Read More
This study objective is to establish the safety and effectiveness of the Edwards SAPIEN 3/ SAPIEN 3 Ultra Transcatheter Heart Valve in subjects with moderate, calcific aortic stenosis. Patients are randomized to S3 TAVR device or medical management. Read More
ALIGN-AR evaluates the safety and probable benefit of the transfemoral JenaValve Pericardial TAVR System in patients with symptomatic severe aortic regurgitation. Patients who are high risk for open surgical aortic valve replacement/repair are eligible. RWJUH is one of only 15 centers in the U.S. that can offer this therapy that has been granted a “Breakthrough Device Designation” by the US Food and Drug Administration. This designation is reserved for investigative therapies designed to treat a serious or life-threatening disease or condition and where preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.
Transcatheter aortic valve replacement for severe AS with a novel deviceEvaluates the safety and efficacy of Acurate (Boston Scientific) valve for transcatheter aortic valve replacement. For patients with severe aortic stenosis who are at intermediate or greater risk for SAVR. Patients are randomized to Acurate or commerical TAVR device. Read More
The study is a prospective, multi-center, randomized controlled pivotal clinical trial to evaluate the safety and effectiveness of the EVOQUE System with optimal medical therapy (OMT) compared to OMT alone in the treatment of patients with at least severe tricuspid regurgitation. Subjects will be followed at discharge, 30 days, 3 months, 6 months and annually through 5 years.
This study will establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable.
The SUMMIT-Tendyne trial (Abbott) evaluates the safety and effectiveness of using the Tendyne Mitral Valve System for the treatment of symptomatic mitral regurgitation or mitral annular calcification in patients who are not appropriate for conventional mitral valve surgery. In the randomized arm, patients are treated with either the Tendyne device or MitraClip, while patients in the non-randomized and MAC arms receive the Tendyne device. https://clinicaltrials.gov/ct2/show/NCT03433274
CLASP IID/F is a prospective, multicenter, randomized, controlled pivotal trial to evaluate the safety and effectiveness of transcatheter mitral valve repair in patients with degenerative/functional mitral regurgitation with the Edwards PASCAL Transcatheter Valve Repair System compared with the commercially available device (Abbott MitraClip).
RESTORE is a prospective, multicenter, non-randomized trial designed to evaluate the safety and effectiveness of the HARPOON™ Beating Heart Mitral Valve Repair System in patients with severe degenerative mitral regurgitation (DMR).